Trials / Unknown
UnknownNCT04636775
Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 46 (estimated)
- Sponsor
- Jun Zhang, MD, PhD · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer, immunotherapy naive participants can predict the effectiveness of immunotherapy treatment as well as determine ahead of time adverse events and their severity. In addition, the investigator will look into microbiome changing modifiers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Microbiome | Nasal and buccal swabs, and stool sample, as well as the extracted DNAs |
Timeline
- Start date
- 2020-07-29
- Primary completion
- 2024-08-30
- Completion
- 2024-12-31
- First posted
- 2020-11-19
- Last updated
- 2023-12-11
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04636775. Inclusion in this directory is not an endorsement.